Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

Matteo Lucchini, Assunta Bianco, Paola Del Giacomo, Chiara De Fino, Viviana Nociti, Massimiliano Mirabella

Research output: Contribution to journalLetterpeer-review

Abstract

The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient.

Original languageEnglish
Article number102323
JournalMultiple Sclerosis and Related Disorders
Volume44
DOIs
Publication statusPublished - Sep 2020

Keywords

  • COVID-19
  • IgA
  • IgG
  • Ocrelizumab
  • Serology

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report'. Together they form a unique fingerprint.

Cite this